MedTrace Logo

Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease

NCT01315795 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2014-07-08

No results posted yet for this study

Summary

An open-label, Phase II clinical study to evaluate the efficacy and safety of lanreotide autogel 90mg every 4 weeks in the treatment of symptomatic polycystic liver disease, including a dose escalation at month 6 to lanreotide autogel 120mg for non responders.

Conditions

  • Polycystic Liver Disease

Interventions

DRUG

Lanreotide Autogel 90 mg and 120 mg

administration of lanreotide sc every 4 weeks (28 days)

Sponsors & Collaborators

  • Ipsen

    collaborator INDUSTRY

  • Universitaire Ziekenhuizen KU Leuven

    lead OTHER

Principal Investigators

  • Frederik Nevens, MD, PhD · UZ Leuven, Gasthuisberg

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2014-07-31
Completion
2014-07-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01315795 on ClinicalTrials.gov